Evidence map›Paper›PMID 35083431›Full record

ArticleCurrent research in biotechnology2021

Highly portable quantitative screening test for prostate-specific antigen at point of care.

Balaji Srinivasan, David M Nanus, David Erickson, Saurabh Mehta

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Current research in biotechnology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
1.4field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 24 citations in OpenAlex.

  1. Trial
  2. FeMikrochimica acta · 2026
    Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. Review
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Balaji SrinivasanDivision of Nutritional Sciences, Cornell University, Ithaca, NY 14853, USA.
David M NanusDivision of Hematology and Medical Oncology, Department of Medicine, Weill Cornell Medicine, New York, NY, USA.
David EricksonDivision of Nutritional Sciences, Cornell University, Ithaca, NY 14853, USA.
Saurabh MehtaDivision of Nutritional Sciences, Cornell University, Ithaca, NY 14853, USA.
Cornell University · US

Funding

Weill Cornell Medicine (WCM) SPORE in Prostate CancerP50CA211024 · NCI · WEILL MEDICAL COLL OF CORNELL UNIV · PI GUDAS, LORRAINE J · 2017 to 2021
$10.9M
FeverPhone: Point of Care Diagnosis of Acute Febrile Illness using a Mobile DeviceR01EB021331 · NIBIB · CORNELL UNIVERSITY · PI ERICKSON, DAVID CARL, MEHTA, SAURABH · 2016 to 2020
$3.0M
NCI NIH HHS P50 CA211024NIBIB NIH HHS R01 EB021331
6 · The paper itself

Abstract

Prostate cancer (PCa) is the second most diagnosed cancer among men. Targeted PCa screening may decrease PCa-specific mortality. Prostate-specific antigen (PSA) is the most reliable and widely accepted tumor biomarker for screening and monitoring PCa status. However, in many settings, quantification of serum PSA requires access to centralized laboratories. In this study, we describe a proof-of-concept rapid test combined with a highly portable Cube

Indexed as

CancerPOCTPoint of careProstate cancerProstate-specific antigenScreening

Identifiers

PMID35083431
PMCPMC8789004
OpenAlexW3212702392

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.